Biomarker-driven
management of NSCLC
Several oncogenic driver alterations are now used as standard in the selection of treatment regimens in non-small cell lung cancer (NSCLC), such as EGFR, ALK, ROS1, BRAF, HER2 and NTRK, with more being discovered.
This expert-led program aims to improve the individualised management of NSCLC through education on the detection of NTRK gene fusions, current evidence-based guidelines, and new and emerging therapies.
There will also be guidance on integrating shared decision making into your clinical practice drawing on insights from a patient on how best to communicate.
This program is aimed at global oncologists, pathologists and those treating patients with NSCLC.
For CME-accredited activities, look for the badge
CME-accredited activities
The importance of shared decision making
eLearning module and downloadable PDF
(0.5 AMA PRA Category 1 Credits™)
Detecting and targeting NTRK fusions in NSCLC
Clinical pathway tool
(0.5 AMA PRA Category 1 Credits™)
